Skip to content

Author

Yeiwei Wu

We have 1 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy.

In mouse xenograft models, the dual-targeting BsADC showed potential anti-tumor activity compared to single-target controls, with no overt body weight loss or observable physical toxicity detected during treatment.

Meng-Huai Wu, Xuezhe Feng, Wen-Qian Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.